SCHEMBL21739082

SCHEMBL21739082

CC(C)N1CCC1CNC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
DRD2 P14416 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
EPHX1 P07099 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
GAA P10253 1/20 0.38
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
CTSK P43235 3/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19088850 0.92 EPHX1 (0.41) GFERKMT2AMEN1DRD2ALDH1A1
SCHEMBL19088851 0.92 EPHX1 (0.41) GFERKMT2AMEN1DRD2ALDH1A1
SCHEMBL25290598 0.78 DRD2 (0.44) GFERKMT2AMEN1DRD2ALDH1A1
SCHEMBL25258556 0.78 DRD2 (0.44) GFERKMT2AMEN1DRD2ALDH1A1
SCHEMBL11024826 0.78 DRD2 (0.45) KMT2ADRD2KDM4ECKS1BSKP1
SCHEMBL1456420 0.77 KMT2A (0.49) KMT2AMEN1DRD2ALDH1A1TSHR
SCHEMBL5167552 0.77 KMT2A (0.51) GFERKMT2AMEN1DRD2EPHX1
SCHEMBL5168538 0.77 KMT2A (0.51) GFERKMT2AMEN1DRD2EPHX1
Hydrochloric Acid SCHEMBL7947555 0.75 KMT2A (0.50) GFERKMT2AMEN1DRD2EPHX1
SCHEMBL23675639 0.75 DRD2 (0.40) GFERKMT2AMEN1DRD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187702-B2 Sulfonamideurea compounds INFLAZOME LIMITED (IE) 2025-01-07 US disclosed
US-20220194923-A1 NOVEL SULFONAMIDEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2022-06-23 US disclosed
US-20220194923-A1 NOVEL SULFONAMIDEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2022-06-23 US disclosed
CN-112672995-A Novel sulfonamide urea compounds 英夫拉索姆有限公司 2021-04-16 CN disclosed
WO-2020035464-A1 NOVEL SULFONAMIDEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194923-A1 NOVEL SULFONAMIDEUREA COMPOUNDS NLRP3, NOD1, NLRP1 GFER 179/4885KMT2A 2977/4885MEN1 3286/4885
US-12187702-B2 Sulfonamideurea compounds NLRP3, NOD1, NLRP1 GFER 121/4885KMT2A 2798/4885MEN1 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.